The initiation of coverage by B of A Securities with a Neutral rating and a price target of $10.5 for Roivant Sciences indicates that the analyst sees the stock as fairly valued. This news is directly related to ROIV and is important for investors, but the Neutral rating suggests that the stock price is not expected to move significantly in the short term.